Dermatology
GUIDELINE
● Guideline
Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report
Frontiers in Medicine
Published April 1, 2026
Zhuochen Wu, Xiaoyu Xie, Wenyu Tang, Yifeng Wu, Guoqiang Zhang, Qing Zhu
DOI ↗
This publication presents a case report and literature review describing the use of guselkumab for inverse psoriasis in a single 48-year-old male patient. The patient received three subcutaneous injections of guselkumab, with follow-up at 12 weeks. The main reported outcome was a marked improvement in cutaneous lesions and pruritus. No specific effect sizes, absolute numbers, or statistical measures were provided for this improvement.
Safety and tolerability data were not reported for this case. The report did not mention any adverse events, serious adverse events, or treatment discontinuations. A comparator group was not included in this single-case description.
Key limitations stem from the study design. The evidence is from a single case report, which provides very low certainty. Generalizability is severely limited, and no conclusions can be drawn about causality, comparative efficacy, or the safety profile of guselkumab for this condition. Funding sources and author conflicts of interest were not reported.
In practice, this case suggests guselkumab may be a therapeutic option worthy of further investigation for inverse psoriasis. However, clinicians should interpret this as a preliminary signal only. Treatment decisions should be based on higher-quality evidence from controlled clinical trials.
Imagine a painful, itchy rash that thrives in the warm, moist folds of your skin—your armpits, groin, or under your breasts. That's inverse psoriasis, and it can be incredibly difficult to treat. Doctors recently tried a newer psoriasis medication, guselkumab, on a 48-year-old man with this condition. After three injections over 12 weeks, his skin lesions and the relentless itching showed marked improvement. This is a promising result for a single patient, offering a glimmer of hope where treatment options are often limited. However, it's crucial to remember this is just one case. We have no way of knowing if this drug would help another person with the same condition, and we don't have any information on side effects or how long the improvement might last. The finding is a starting point for asking new questions, not a proven solution.
What this means for you: One patient improved, but it's too soon to know if this treatment works for others.
View Original Abstract ↓
Inverse psoriasis is a special type of psoriasis whose pathogenesis is not yet fully understood, and for which there is no consensus guideline due to marked therapeutic challenges associated with the specific anatomic location of lesions. Immune-mediated inflammation plays a key role in its development, and the lesions are susceptible to friction and humidity, which makes the affected area less tolerant to treatment. In this article, we report a successful case of Inverse psoriasis treated with Guselkumab in a 48-years-old male, who was treated with three subcutaneous injections of Guselkumab and exhibited marked improvement in cutaneous lesions and pruritus at 12 weeks of treatment. A review of the relevant literature was also conducted with the aim of providing clinicians with more references for the treatment of this disease.
